Desimmie, B. A. et al. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J. Mol. Biol. 426, 1220–1245 (2014).

Article  CAS  PubMed  Google Scholar 

Hu, Y., Knecht, K. M., Shen, Q. & Xiong, Y. Multifaceted HIV-1 Vif interactions with human E3 ubiquitin ligase and APOBEC3s. FEBS J. 288, 3407–3417 (2021).

Article  CAS  PubMed  Google Scholar 

Salamango, D. J. & Harris, R. S. Demystifying cell cycle arrest by HIV-1 Vif. Trends Microbiol. 29, 381–384 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646–650 (2002).

Article  CAS  PubMed  Google Scholar 

Chaipan, C., Smith, J. L., Hu, W. S. & Pathak, V. K. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J. Virol. 87, 444–453 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Desimmie, B. A. et al. APOBEC3 proteins can copackage and comutate HIV-1 genomes. Nucleic Acids Res. 44, 7848–7865 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hultquist, J. F. et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85, 11220–11234 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Refsland, E. W., Hultquist, J. F. & Harris, R. S. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog. 8, e1002800 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Conticello, S. G. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 9, 229 (2008).

Article  PubMed  PubMed Central  Google Scholar 

Harris, R. S. et al. DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803–809 (2003).

Article  CAS  PubMed  Google Scholar 

Lecossier, D., Bouchonnet, F., Clavel, F. & Hance, A. J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300, 1112 (2003).

Article  CAS  PubMed  Google Scholar 

Mangeat, B. et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99–103 (2003).

Article  CAS  PubMed  Google Scholar 

Adolph, M. B., Webb, J. & Chelico, L. Retroviral restriction factor APOBEC3G delays the initiation of DNA synthesis by HIV-1 reverse transcriptase. PLoS ONE 8, e64196 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bishop, K. N., Verma, M., Kim, E. Y., Wolinsky, S. M. & Malim, M. H. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4, e1000231 (2008).

Article  PubMed  PubMed Central  Google Scholar 

Holmes, R. K., Koning, F. A., Bishop, K. N. & Malim, M. H. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282, 2587–2595 (2007).

Article  CAS  PubMed  Google Scholar 

Iwatani, Y. et al. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35, 7096–7108 (2007).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li, X. Y., Guo, F., Zhang, L., Kleiman, L. & Cen, S. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 282, 32065–32074 (2007).

Article  CAS  PubMed  Google Scholar 

Luo, K. et al. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81, 7238–7248 (2007).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mbisa, J. L. et al. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81, 7099–7110 (2007).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mbisa, J. L., Bu, W. & Pathak, V. K. APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J. Virol. 84, 5250–5259 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Newman, E. N. et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15, 166–170 (2005).

Article  CAS  PubMed  Google Scholar 

Pollpeter, D. et al. Deep sequencing of HIV-1 reverse transcripts reveals the multifaceted antiviral functions of APOBEC3G. Nat. Microbiol. 3, 220–233 (2018).

Article  CAS  PubMed  Google Scholar 

Dang, Y., Wang, X., Esselman, W. J. & Zheng, Y. H. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80, 10522–10533 (2006).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marin, M., Rose, K. M., Kozak, S. L. & Kabat, D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9, 1398–1403 (2003).

Article  CAS  PubMed  Google Scholar 

Mehle, A. et al. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279, 7792–7798 (2004).

Article  CAS  PubMed  Google Scholar 

OhAinle, M., Kerns, J. A., Malik, H. S. & Emerman, M. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol. 80, 3853–3862 (2006).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sheehy, A. M., Gaddis, N. C. & Malim, M. H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9, 1404–1407 (2003).

Article  CAS  PubMed  Google Scholar 

Shirakawa, K. et al. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex. Virology 344, 263–266 (2006).

Article  CAS  PubMed  Google Scholar 

Stopak, K., de Noronha, C., Yonemoto, W. & Greene, W. C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12, 591–601 (2003).

Article  CAS  PubMed  Google Scholar 

Wiegand, H. L., Doehle, B. P., Bogerd, H. P. & Cullen, B. R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23, 2451–2458 (2004).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu, X. et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056–1060 (2003).

Article  CAS  PubMed  Google Scholar 

Zheng, Y. H. et al. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78, 6073–6076 (2004).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jager, S. et al. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 481, 371–375 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Zhang, W., Du, J., Evans, S. L., Yu, Y. & Yu, X. F. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481, 376–379 (2011).

Article  PubMed  Google Scholar 

Sakai, K., Dimas, J. & Lenardo, M. J. The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc. Natl Acad. Sci. USA 103, 3369–3374 (2006).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, J. et al. The Vif accessory protein alters the cell cycle of human immunodeficiency virus type 1 infected cells. Virology 359, 243–252 (2007).

Article